Pluri Inc. Proceeds from Debt, Net of Issuance Costs
Pluri Inc. (PLUR) reported Proceeds from Debt, Net of Issuance Costs of $3.00 thousand for the 9-month period ending 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2026-09-10
- 2026-03-31: Proceeds from Debt, Net of Issuance Costs 9 month $3.00K.
- 2025-04-28: Proceeds from Debt, Net of Issuance Costs $47.00K.
| Period end | Proceeds from Debt, Net of Issuance Costs | Proceeds from Debt, Net of Issuance Costs 9 month |
|---|---|---|
| 2026-03-31 | $3.00K 10-Q · filed 2026-05-14 | |
| 2025-04-28 | $47.00K 10-K · filed 2026-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |